View in EDS HTML Full Text PDF Full Text

Pharmacokinetic, Safety, and Immunogenicity Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501, Adalimumab-Atto.

Saved in:
Bibliographic Details
Title: Pharmacokinetic, Safety, and Immunogenicity Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501, Adalimumab-Atto.
Authors: Chow V; Amgen Inc., Thousand Oaks, California, USA., Zhou M; Amgen Inc., Thousand Oaks, California, USA., Mytych DT; Amgen Inc., Thousand Oaks, California, USA., Colbert A; Amgen Inc., Thousand Oaks, California, USA., Miller MJ; Amgen Inc., Thousand Oaks, California, USA., Wala I; Amgen Inc., Thousand Oaks, California, USA., Sabet A; Icon, Salt Lake City, Utah, USA., Radziszewski W; Amgen Inc., Thousand Oaks, California, USA.
Source: Pharmacology research & perspectives [Pharmacol Res Perspect] 2026 Apr; Vol. 14 (2), pp. e70236.
Publication Type: Journal Article; Randomized Controlled Trial
Journal Info: Publisher: John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 101626369 Publication Model: Print Cited Medium: Internet ISSN: 2052-1707 (Electronic) Linking ISSN: 20521707 NLM ISO Abbreviation: Pharmacol Res Perspect Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41857488
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Pharmacokinetic, Safety, and Immunogenicity Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501, Adalimumab-Atto.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Chow+V%22">Chow V</searchLink>; Amgen Inc., Thousand Oaks, California, USA.<br /><searchLink fieldCode="AU" term="%22Zhou+M%22">Zhou M</searchLink>; Amgen Inc., Thousand Oaks, California, USA.<br /><searchLink fieldCode="AU" term="%22Mytych+DT%22">Mytych DT</searchLink>; Amgen Inc., Thousand Oaks, California, USA.<br /><searchLink fieldCode="AU" term="%22Colbert+A%22">Colbert A</searchLink>; Amgen Inc., Thousand Oaks, California, USA.<br /><searchLink fieldCode="AU" term="%22Miller+MJ%22">Miller MJ</searchLink>; Amgen Inc., Thousand Oaks, California, USA.<br /><searchLink fieldCode="AU" term="%22Wala+I%22">Wala I</searchLink>; Amgen Inc., Thousand Oaks, California, USA.<br /><searchLink fieldCode="AU" term="%22Sabet+A%22">Sabet A</searchLink>; Icon, Salt Lake City, Utah, USA.<br /><searchLink fieldCode="AU" term="%22Radziszewski+W%22">Radziszewski W</searchLink>; Amgen Inc., Thousand Oaks, California, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101626369%22">Pharmacology research & perspectives</searchLink> [Pharmacol Res Perspect] 2026 Apr; Vol. 14 (2), pp. e70236.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22John+Wiley+%26+Sons+Ltd%2C+British+Pharmacological+Society+and+American+Society+for+Pharmacology+and+Experimental+Therapeutics%22">John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101626369 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2052-1707 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220521707%22">20521707 </searchLink><i>NLM ISO Abbreviation: </i>Pharmacol Res Perspect <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41857488
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/prp2.70236
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e70236
    Titles:
      – TitleFull: Pharmacokinetic, Safety, and Immunogenicity Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501, Adalimumab-Atto.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Chow V
      – PersonEntity:
          Name:
            NameFull: Zhou M
      – PersonEntity:
          Name:
            NameFull: Mytych DT
      – PersonEntity:
          Name:
            NameFull: Colbert A
      – PersonEntity:
          Name:
            NameFull: Miller MJ
      – PersonEntity:
          Name:
            NameFull: Wala I
      – PersonEntity:
          Name:
            NameFull: Sabet A
      – PersonEntity:
          Name:
            NameFull: Radziszewski W
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2026 Apr
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2052-1707
          Numbering:
            – Type: volume
              Value: 14
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Pharmacology research & perspectives
              Type: main
ResultId 1